Open Access. Powered by Scholars. Published by Universities.®

Medicine and Health Sciences Commons

Open Access. Powered by Scholars. Published by Universities.®

Arts and Humanities

University of South Florida

2011

Microglia

Articles 1 - 2 of 2

Full-Text Articles in Medicine and Health Sciences

An Observation Of Immunological Effect, A Diet Enhanced With Spirulina And Treatment With Fractalkine In Models Of Parkinson's Disease, Mibel M. Pabón Mar 2011

An Observation Of Immunological Effect, A Diet Enhanced With Spirulina And Treatment With Fractalkine In Models Of Parkinson's Disease, Mibel M. Pabón

USF Tampa Graduate Theses and Dissertations

In my dissertation research we used use human wild type α-synuclein gene expression using an adeno-associated viral vector (AAV9) that induced a slowly progressive loss of dopamine (DA) neurons in the Substantia nigra (SN) as one of our animal model of Parkinson’s disease (PD). It is our hypothesis that neuroinflammation predisposes the brain to susceptibility to neurodegenerative diseases. Thus we examined the progression of a PD lesion and examined the manipulations of the immune system to understand further the inflammatory role when we administered exogenous soluble fractalkine.

The specific etiology of neurodegeneration in PD is unknown, but the inflammatory mechanisms …


The Role Of Hiv-1 Proteins In Alzheimer's Disease Pathology, Brian Nelson Giunta Jan 2011

The Role Of Hiv-1 Proteins In Alzheimer's Disease Pathology, Brian Nelson Giunta

USF Tampa Graduate Theses and Dissertations

Prevalence of HIV-associated cognitive impairment is rising, the worst form of which is HIV-associated dementia (HAD). The disease is fuiled by a chronic innate type pro-inflammatory response in the brain which is highly dependent upon the activation of microglia. We first created an in vitro model of HAD composed of cultured microglial cells synergistically activated by the addition of IFN-gamma and the HIV-1 coat glycoprotein, gp120. This activation, as measured by TNF-alpha and NO release, is synergistically attenuated through the alpha7nAChR and p44/42 MAPK system by pretreatment with nicotine, and the cholinesterase inhibitor, galantamine. As these medications have been FDA …